Yazan Numan

Yazan Numan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YNYazan Numan
Yazan Numan
ZRZaid Abdel Rahman
Zaid Abdel Rahman
JGJustin Grenet
Justin Grenet
SBStephanie Boisclair
Stephanie Boisclair
JBJan Bewersdorf
Jan Bewersdorf
JAJessica K. Altman
Jessica K. Altman

1 September 2017 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
RHRay. Y. Hachem
Ray. Y. Hachem
AAAndrew Assaf
Andrew Assaf
YNYazan Numan
Yazan Numan
PSPankil Shah
Pankil Shah
YJYing Jiang
Ying Jiang
IRIssam I. Raad
Issam I. Raad

1 July 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ACAnne-Marie Chaftari
Anne-Marie Chaftari
RHRay Hachem
Ray Hachem
ASAriel Szvalb
Ariel Szvalb
MTMahnaz Taremi
Mahnaz Taremi
BGBruno Granwehr
Bruno Granwehr
IRIssam Raad
Issam Raad
For long-term central lines (CL), the lumen is the major source of central line-associated bloodstream infections (CLABSI). The current standard of care for maintaining catheter patency includes flushing the CL with saline or heparin. Neither agent has any antimicrobial activity. Furthermore, heparin may enhance staphylococcal biofilm formation. We evaluated the safety and efficacy of a novel nonantibiotic catheter lock solution for the prevention of CLABSI. Between November 2015 and February 2016, we enrolled 60 patients with hematologic malignancies who had peripherally inserted central catheters (PICC) to receive the study lock solution. The study lock consisted of 15 or 30 μg/ml of nitroglycerin in combination with 4% sodium citrate and 22% ethanol. Each lumen was locked for at least 2 h once daily prior to being flushed. After enrollment of 10 patients at the lower nitroglycerin dose without evidence of toxicity, the dose was escalated to the higher dose (30 μg/ml). There were no serious related adverse events or episodes of hypotension with lock administration. Two patients experienced mild transient adverse events (one headache and one rash) possibly related to the lock and that resolved without residual effect. The CLABSI rate was 0 on lock days versus 1.6/1,000 catheter days (CD) off lock prophylaxis, compared with a rate of 1.9/1,000 CD at the institution in the same patient population. In conclusion, the nitroglycerin-based lock prophylaxis is safe and well tolerated. It may prevent CLABSI when given daily to cancer patients. Large, prospective, randomized clinical trials are needed to validate these findings. (This study has been registered at ClinicalTrials.gov under identifier NCT02577718.)

Verified
Journal Article
Open access
PDF file
YNYazan Numan
Yazan Numan
YJYasir Jawaid
Yasir Jawaid
HHHisham Hirzallah
Hisham Hirzallah
DKDamir Kusmic
Damir Kusmic
MMMohammad Megri
Mohammad Megri
YSYousef Shweihat
Yousef Shweihat
Objective: The use of serum ammonia as a novel marker for sepsis compared to lactic acid levels in intensive care unit (ICU) patients. Design and Interventions: Single arm, prospective clinical trial to collect arterial blood samples from patients with sepsis. Serial ammonia and lactic acid levels were sent every six hours for a total of three days. Measurements and results: Compare mean levels of ammonia and lactic acid in terms of diagnosing sepsis and patient outcome, including length of stay and mortality. A total of 30 patients were enrolled in the pilot study. On admission, mean ammonia level was 35.7 μmol/L and lactic acid was 3.06 mmole/L. Ammonia levels checked at the end of day 2 (ammonia 2-4) and the beginning of day 3 (ammonia 3-1) were higher in patients who had a microbial culture-proven sepsis (p-values 0.029 and 0.002, respectively) compared to those without culture-positive sepsis. Ammonia levels did predict a longer hospital stay; ammonia level of more than 40 μmol/L had a mean hospital stay of 17.6 days vs. patients with normal levels who had a mean hospital stay of 9.62 days (p-value 0.0082). Conclusion: Elevated ammonia level can be a novel biomarker for sepsis, comparable to conventional markers. Ammonia levels have a prognostic utility as elevated levels were associated with longer hospital stay.

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ACAnne-Marie Chaftari
Anne-Marie Chaftari
RHRay Hachem
Ray Hachem
ASAriel Szvalb
Ariel Szvalb
MTMahnaz Taremi
Mahnaz Taremi
BGBruno Granwehr
Bruno Granwehr
IRIssam Raad
Issam Raad
Volume 61, no. 7, e00091-17, 2017, [https://doi.org/10.1128/AAC.00091-17][1]. Page 1: the 7th author's name should be Sapna Amin rather than Amin Sapna. The corrected author list appears above. [1]: /lookup/doi/10.1128/AAC.00091-17

1 October 2017 in Chest
Verified
Journal Article
Closed access
PDF file
YNYazan Numan
Yazan Numan
OAObada Aqtash
Obada Aqtash
MMMunthir Mansour
Munthir Mansour
YSYousef Shweihat
Yousef Shweihat
TGTodd Gress
Todd Gress
MJMuhammad Jamil
Muhammad Jamil